Under this agreement, Cipla will be responsible for obtaining regulatory approval from Drug Controller General of India (DCGI) to distribute Afrezza in India. Cipla will market and distribute this drug in India while MannKind will supply Afrezza to Cipla.
MannKind will receive a $2.2mn upfront payment from Cipla within 30 days of entering the agreement, with the potential to receive additional regulatory milestone payments, minimum purchase commitment revenue and royalties on Afrezza sales in India.
Afrezza, is a rapid-acting insulin, delivered in powder form through an innovative drug delivery system. It is available by prescription only.
As per the medical report, the action curve of subcutaneous insulin injections lags behind that of pancreatically-produced insulin i.e. the rapid insulin starts working approximately 15 minutes after injection/infusion, peaks in 60-90 minutes and lasts a full 3-5 hours. Despite this, Afrezza sales are yet to show meaningful sales in the US market.